Hyperbaric Oxygen and Aging: The Dose Nobody Sells

The trial that built an industry

In November 2020, a group at the Sagol Center for Hyperbaric Medicine at Shamir Medical Center in Israel published a result that has been quoted in every hyperbaric brochure written since. Thirty-five healthy, independently living adults aged 64 and over were enrolled; thirty completed. Their mean age was 68.4. Over three months they breathed pure oxygen under pressure, and their immune cells came out looking younger.^[1]

The numbers are genuinely arresting. Telomere length — the protective sequence at the end of each chromosome that shortens as cells divide — rose in every lymphocyte subset measured. B cells gained 37.63% by the end of follow-up. T helper cells gained 29.30%, natural killer cells 20.56%, cytotoxic T cells 19.59%. At the same time the proportion of senescent T helper cells fell by 37.30%, and senescent cytotoxic T cells by 10.96%.

Taken at face value, that is a simultaneous reversal of two of the canonical hallmarks of aging in a healthy human population, achieved without a drug. Nothing else in the longevity clinic can claim as much. It is entirely understandable that the field seized on it.

It is also, on close reading, a much more fragile finding than its afterlife suggests.

Read the error bars

Return to the B-cell figure, and write it out in full as the authors did: 37.63% ± 52.73.^[1]

The standard deviation is roughly one and a half times the mean. In plain terms: the average participant's B-cell telomeres lengthened substantially, but the spread around that average was enormous. Some people almost certainly moved very little, and the mean was carried by a subset who moved a great deal. The T helper figure, 29.30% ± 38.51, has the same shape. So does the cytotoxic result, 19.59% ± 33.98.

This is not a criticism of the investigators, who reported their dispersion honestly and listed their own limitations plainly: a small sample, no control arm, unmeasured telomerase activity, and no data on how long any of it lasts once the chamber door opens for the last time.^[1] It is a criticism of everyone who has since quoted "a 20% increase in telomere length" as though it were a dependable, per-person specification.

And the absence of a control group matters more here than in most trials. Telomere measurement in isolated blood cells is technically demanding and drifts with sample composition, and immune-cell populations shift over three months for many reasons unrelated to oxygen. Without a parallel group measured on the same instruments over the same period, the intervention cannot be separated from the assay. The paper is a well-executed signal, not an effect size you can bank.

Ninety hours, not ninety minutes

Here is the part that almost never survives the journey from journal to sales page. The protocol was not gentle, and it was not brief.

Participants received 60 daily sessions, five days a week, over three months. Each session was 90 minutes of 100% oxygen delivered by mask at 2.0 ATA — twice sea-level atmospheric pressure — with a five-minute air break every 20 minutes to reduce the risk of oxygen toxicity.^[1]

Do the arithmetic. Ninety minutes times sixty sessions is 90 hours inside the chamber. Subtract three five-minute air breaks per session and the actual exposure to pure molecular oxygen (O₂) at pressure is 75 hours. This was, for three months, close to a part-time job.

Now consider what is actually being sold. The wellness market has standardised on soft-shell chambers at 1.3 ATA, in sessions of roughly 60 minutes, taken once or twice a week. Vendor pricing guides in 2026 put those soft-shell units at roughly $5,000–$10,000 to buy, against $28,000 to well over $100,000 for a hard-shell chamber capable of the 2.0 ATA the research used.

That last row deserves a moment. Breathing ordinary air at sea level, inspired oxygen partial pressure sits near 150 mmHg. A 1.3 ATA chamber pressurised with room air — which is how a good many soft-shell units are operated — lifts that to roughly 200 mmHg. It is an increase of about a third. The trials were working at nearly ten times sea-level inspired pressure. These are not two doses of the same medicine. They are arguably not the same intervention.

Why the pressure is the mechanism, not the packaging

It would be convenient if oxygen worked linearly, so that a third of the pressure bought a third of the benefit. The proposed mechanism suggests otherwise.

The favoured explanation is the hyperoxic–hypoxic paradox. Repeated surges of very high oxygen — each followed by a return to normal air — are read by the cell as though oxygen were becoming scarce. That triggers hypoxia-inducible factor 1α (HIF-1α) and the regenerative programme normally reserved for low-oxygen stress, while hyperoxia additionally induces SIRT1.^[6] The active ingredient is not oxygen abundance but the swing: the steepness of the rise and fall, delivered often enough to register.

If that model is right, then modest pressure applied infrequently does not deliver a diluted version of the effect. It may fail to cross the threshold that produces any effect at all. The same review that set out this mechanism was candid that "the durability of these beneficial changes is yet to be determined."^[6] Six years on, it still is.

Readers who have followed our coverage of senolytics and the clearance of senescent cells will recognise the pattern: an intervention with a plausible cellular story, an early human signal, and a commercial layer that has run far ahead of the dose-response data.

The cognitive trial, and the sham that was missing

The second pillar of the HBOT longevity case is a randomised controlled trial from the same centre, published four months earlier. Sixty-three healthy adults over 64 were randomised to three months of HBOT (n = 33) or to control (n = 30). Global cognitive function improved significantly in the treated group, with a group-by-time interaction of p = 0.0017. The largest gains were in attention (net effect size 0.745) and information processing speed (0.788) — precisely the domains that erode first with age. Perfusion MRI showed corresponding increases in cerebral blood flow across frontal and parietal regions.^[2]

This is a real randomised trial and it deserves respect. But note what the control arm was: no treatment. Not a sham chamber, not a low-pressure decoy. The participants knew whether they had spent three months being pressurised, and so, in the cognitive testing room, did expectation.

For an outcome as suggestible as attention and processing speed, measured by repeat neuropsychological testing, that is a consequential gap. It does not void the result. It does mean the effect size is an upper bound, and that the honest comparison — sixty sessions of real pressure against sixty sessions of convincing theatre — has still not been published. We have made the same observation about therapeutic plasma exchange, where two trials of a fashionable clinic procedure reached different conclusions largely on the strength of their control design.

What the reviewers concluded

In April 2024 a team at the Dallas Plastic Surgery Institute ran the first systematic review of hyperbaric oxygen in aesthetic medicine and anti-aging, published in Aesthetic Plastic Surgery. They screened 591 articles. Fifty-three looked potentially relevant. After independent full-text review by two authors, fifteen met inclusion criteria.^[3]

Their verdict is worth quoting close to verbatim: HBOT may serve as a valuable adjunct, but the evidence to support its use, and to justify its cost, is limited. They called for large-scale randomised trials with standardised protocols before the question can be settled.^[3]

Fifteen papers is not a literature. It is a promising beginning that has been marketed as a conclusion.

The risks that stay off the brochure

Hyperbaric oxygen is a genuine medical therapy with approved indications, and at those indications it is well tolerated. It is not, however, a spa treatment, and the adverse-event profile is not zero.

A 2025 multicentre Italian review examined 1,799 sessions delivered to 69 patients aged 75 and older at 2.4–2.8 ATA. Side effects occurred in 20.3% of patients: middle ear barotrauma in 8.7%, sinus barotrauma in 4.3%, confinement anxiety in 4.3%, hypoglycaemia in 1.4% and chest pain in 1.4%. Most resolved with prompt care, and there were no life-threatening events. The authors' conclusion was reassuring but conditional: HBOT is safe in the elderly when strict pre-treatment evaluation and monitoring protocols are implemented — in their centres, ENT examination, ECG, chest radiography and bloods before starting.^[4]

Two details are relevant to anyone considering a course for longevity rather than for disease. First, middle ear barotrauma becomes more common with increasing age and is significantly more frequent in women, in a four-year cohort of every patient treated at a single centre.^[5] Second, confinement anxiety at 4.3% is not trivial when the proposal is sixty consecutive weekday sessions.

How to read an offer

None of this makes hyperbaric oxygen a fraud. It makes it an intervention whose evidence is specific — to a pressure, a duration, a frequency and a population — being sold in a form that has quietly abandoned all four specifications.

If a clinic presents the telomere data, four questions separate the serious operator from the decorative one. What pressure, in ATA, and is it a hard-shell chamber? Is the oxygen 100% by mask, or is the unit simply pressurising room air? How many sessions constitute the protocol, and over how many weeks? And what pre-treatment screening — ears, chest, glucose — is done before the first session?

An operator who can answer all four is offering the thing that was studied. An operator who deflects to "cellular oxygenation" is offering a nap in a pressurised bag. The price gap between them is often smaller than you would expect, which tells you something about where the margin lives.

The deeper point is one we return to often. A measurement that moves is not the same as a life that lengthens. Telomere length rose in thirty people over three months; whether that buys anybody a single additional healthy year is unknown, and will remain so until someone runs the sham-controlled trial the field has avoided for six years. Until then, do what we would recommend before any biological-age intervention: establish what your baseline actually is, and remember that immune aging is measured on more than one axis.